Completed
The Cancer-Immunity Cycle-Targeting Opportunities
Class Central Classrooms beta
YouTube videos curated by Class Central.
Classroom Contents
Immunotherapy for Gynecological Cancers
Automatically move to the next video in the Classroom when playback concludes
- 1 Intro
- 2 Five years Survival in Gynecologic Cancers 2005-2011
- 3 Chemotherapy Gynecologic Cancers
- 4 The Cancer-Immunity Cycle-Targeting Opportunities
- 5 Cancer and the Surrounding Tissue (Tumor Microenvironment)
- 6 The Cancer Cell Shield against Attack from the Immune System
- 7 Targeting the PD-L1/PD-1 Immune Checkpoint in Ovarian Cancer
- 8 Immune Check Point Inhibitors targeting PDL1 or PD1
- 9 Complete Response to Nivolumab in two Patients with Platinum Resistant Ovarian Cancer
- 10 Overall Best Response to Nivolumab in Patients with Platinum Resistant Ovarian Cancer
- 11 Effect of HPV targeted Tumor infiltrating T Cells on Cervical Cancer
- 12 Generation of Tumor Associated Antigen specific T Cells via Expression of TCR or CAR
- 13 CAR and TCR Cancer Clinical Trials in the US 1994 - 2014
- 14 Increase in Cell Persistence following lymphodepleting. preconditioning Chemotherapy prior to Adoptive Cell Transfer
- 15 Adoptive T Cell Therapy: Directing the Immune System against Ovarian Cancer Cells
- 16 Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients with Metastatic Synovial Ceil Sarcoma and Melanoma
- 17 Treatment of Patients with Metastatic Synovial Cell Sarcoma with Autologous T Cells Expressing TCRs Specific for NY-ESO-1
- 18 Immunotherapy Trials for Ovarian Cancer Stanford Gynecologic Oncology
- 19 The Clinical Research Group for Gynecologic Oncology Clinical Trials
- 20 Stanford Gynecologic Oncology Service Stanford Women's Cancer Center and Stanford Cancer Institute
